Population-based study of pseudoprogression after chemoradiotherapy in GBM.

摘要: Introduction: Chemoradiotherapy followed by monthly temozolomide (TMZ) is the standard of care for patients with glioblastoma multiforme (GBM). Case reports have identified GBM who experienced transient radiological deterioration after concurrent chemoradiotherapy which stabilized or resolved additional cycles adjuvant TMZ, a phenomenon known as radiographic pseudoprogression. Little about natural history Methods: We retrospectively evaluated incidence pseudoprogression in population-based cohort and determined its relationship outcome MGMT promoter methylation status. Results: Out 43 evaluable patients, 25 (58%) exhibited progression on first MRI treatment. Twenty these went to receive subsequent investigation demonstrated 10 cases (50%). Median survival (MS) was better (MS 14.5 months) compared those true radiologic 9.1 months, p=0.025). The MS similar stabilized/responded during treatment (p=0.31). Neither extent initial resection nor dexamethasone dosing associated Conclusions: These data suggest that physicians should continue TMZ when early scans show evidence following chemoradiotherapy, up 50% will experience stability improvement cycles.